Daklinza (Daclatasvir)

 

Medical Evidence Daklinza

Generic name : Daclatasvir.

Trade name : Daklinza.

Manufacturer information :

Daklinza is manufactured by Bristol Myers Squibb.

Daklinza FDA Approval :

Daklinza first approved Date of approval: 27.08.2014.

Daklinza Dosage form :

30 mg film-coated tablets.

Daklinza Indications and Usage :

  • The treatment of the treat adults with hepatitis C. after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.
  • The treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.

Daklinza (Daclatasvir) availability in India

  • You could import this medicine against import permit on Patient Name.
  • Please contact ACT Lifesciences Private Limited for further information.